These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24190980)

  • 1. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs.
    Jardim DL; Hess KR; Lorusso P; Kurzrock R; Hong DS
    Clin Cancer Res; 2014 Jan; 20(2):281-8. PubMed ID: 24190980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determinants of the recommended phase 2 dose of molecular targeted agents.
    Hansen AR; Cook N; Amir E; Siu LL; Abdul Razak AR
    Cancer; 2017 Apr; 123(8):1409-1415. PubMed ID: 28182250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs.
    Mittapalli RK; Yin D; Beaupre D; Palaparthy R
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):23-30. PubMed ID: 33237334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials.
    Hazim A; Mills G; Prasad V; Haslam A; Chen EY
    J Natl Compr Canc Netw; 2020 Apr; 18(4):428-433. PubMed ID: 32259790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of dose escalation for FDA-approved products treating solid tumors and hematological malignancies in first-in-human trials.
    Jiang Z; Sun W; Du R; Yang R
    Clin Transl Oncol; 2024 Sep; 26(9):2116-2125. PubMed ID: 38558284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013.
    Nikanjam M; Liu S; Kurzrock R
    Int J Cancer; 2016 Nov; 139(9):2135-41. PubMed ID: 27389805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting success in regulatory approval from Phase I results.
    Malik L; Mejia A; Parsons H; Ehler B; Mahalingam D; Brenner A; Sarantopoulos J; Weitman S
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1099-103. PubMed ID: 25245822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.
    Penel N; Duhamel A; Adenis A; Devos P; Isambert N; Clisant S; Bonneterre J
    Invest New Drugs; 2012 Apr; 30(2):653-61. PubMed ID: 21049280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials.
    Yokota T; Bendell J; LoRusso P; Tsushima T; Desai V; Kenmotsu H; Watanabe J; Ono A; Murugesan B; Silva J; Naito T; Greenberg J; Kumar P; Wang Y; Jikoh T; Shiga R; Hyman DM; Ho AL; Spriggs DR; Schwartz GK; Gounder MM
    Br J Cancer; 2018 Jun; 118(12):1571-1579. PubMed ID: 29795308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.
    Lu D; Lu T; Stroh M; Graham RA; Agarwal P; Musib L; Li CC; Lum BL; Joshi A
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):459-76. PubMed ID: 26811176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors.
    Jardim DL; de Melo Gagliato D; Giles FJ; Kurzrock R
    Clin Cancer Res; 2018 Apr; 24(8):1785-1794. PubMed ID: 29212781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early phase clinical trial played a critical role in the Food and Drug Administration-approved indications for targeted anticancer drugs: a cross-sectional study from 2012 to 2021.
    Huang Y; Xiong W; Zhao J; Li W; Ma L; Wu H
    J Clin Epidemiol; 2023 May; 157():74-82. PubMed ID: 36905971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.
    van Brummelen EM; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
    J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):235-42. PubMed ID: 26960536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
    Shepshelovich D; Tibau A; Goldvaser H; Molto C; Ocana A; Seruga B; Amir E
    J Clin Oncol; 2018 Jun; 36(18):1798-1804. PubMed ID: 29641296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse.
    Jain RK; Lee JJ; Hong D; Markman M; Gong J; Naing A; Wheler J; Kurzrock R
    Clin Cancer Res; 2010 Feb; 16(4):1289-97. PubMed ID: 20145187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials.
    Rami A; DuBois SG; Campbell K
    Clin Trials; 2024 Apr; 21(2):211-219. PubMed ID: 37961910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose.
    Altzerinakou MA; Collette L; Paoletti X
    J Natl Cancer Inst; 2019 Nov; 111(11):1179-1185. PubMed ID: 30838405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved.
    Zhang SX; Fergusson D; Kimmelman J
    J Natl Cancer Inst; 2020 Sep; 112(9):886-892. PubMed ID: 32239146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.